Core Insights - Insiders are accumulating shares in three companies—Alkami Technology, AdaptHealth, and Tecnoglass—trading near multi-year lows, indicating confidence in their underlying cash generation and demand despite current pressures [2][4]. Alkami Technology (ALKT) - Alkami reported Q4 revenue of $120.79 million, a 34.7% increase year-over-year, with adjusted EBITDA nearly doubling to $19.14 million [7]. - The company has a net dollar retention rate of 115% and an annual recurring revenue (ARR) churn rate below 1% [7]. - General Atlantic purchased 2.8 million shares at prices between $17.35 and $18.41, despite a 28.71% decline in stock price over the past year [6][7]. - Management projects FY2026 revenue between $525.5 million and $530.5 million, with adjusted EBITDA of $93.5 million to $97.5 million [7]. AdaptHealth (AHCO) - AdaptHealth's operating cash flow for the full year reached $601.77 million, an 11.06% increase year-over-year [9]. - Richard Cashin acquired 2 million shares at approximately $9.73, although the stock has seen a 71.5% decline over the past five years [8][9]. - The company faced a significant earnings miss due to a $128 million non-cash goodwill impairment in its Diabetes Health unit [9]. - Management guided FY2026 adjusted EBITDA to be between $680 million and $730 million, with free cash flow projected at $175 million to $225 million [9]. Tecnoglass (TGLS) - Tecnoglass reported record Q4 revenue of $245.30 million, a 16.1% increase year-over-year, and holds a record backlog of $1.30 billion [10]. - The stock has declined 31.17% over the past year, influenced by margin compression from high aluminum costs and currency fluctuations [10]. - Energy Holding has been accumulating shares near 52-week lows, reflecting confidence in the company's future revenue visibility [10]. - The forward P/E ratio is approximately 10x, with an analyst consensus target of $66.25, indicating significant upside potential from the current price of $45.71 [10].

AdaptHealth Conference Call Summary Company Overview - **Company**: AdaptHealth (NasdaqCM: AHCO) - **Industry**: Durable Medical Equipment (DME) Key Points and Arguments Transition Year and Operational Improvements - 2025 was described as a transition year focused on streamlining operations and technology investments [1][2] - The sales force was decoupled from operations to create a core commercial organization, with a successful implementation of a new commissions program [3][4] - Standardization of operating models across regions was achieved, enhancing efficiency in patient setup and deliveries [4][5] Technology and Automation - Significant investments were made in technology to improve operational efficiency, including AI chatbots to optimize scheduling and setup processes [6][7] - The average setup time for patients improved from 17-18 days to 9 days by the end of 2025, aided by technology and virtual setups [6][10] Growth and Market Position - AdaptHealth ended 2025 with a strong infrastructure to support a new capitated contract with Kaiser Permanente, serving over 12 million members [5][24] - The company reported record census growth in sleep, respiratory, and DME categories, with a focus on increasing conversion ratios for referrals [23][24] Resupply Operations - AdaptHealth's resupply operations for sleep and diabetes have shown strong performance, with the company resupplying patients over 2.9 times per year compared to the industry average of 2.1-2.2 times [13][14] - The diabetes segment is experiencing a shift towards pharmacy reimbursement, with efforts to stabilize payer mix and increase sales [46][49] Regulatory Environment and M&A Activity - A recent moratorium on new DME provider numbers was implemented due to fraud concerns, which may impact M&A activities [27][32] - AdaptHealth has successfully divested non-core business lines and is open to further portfolio adjustments based on market conditions [40][42] Partnerships and Contracts - The company has secured multi-year contracts with major payers like Humana and Kaiser, with positive membership growth and operational performance [55][56] - AdaptHealth is exploring additional capitated contracts with large hospital systems, leveraging its experience with existing partnerships [78][79] Challenges and Future Outlook - The company anticipates ongoing pressure from payers to shift towards pharmacy benefits, which may affect revenue growth in the diabetes segment [48][50] - Despite challenges, AdaptHealth remains optimistic about growth opportunities and the potential for new contracts in the DME space [79][80] Additional Important Insights - The company has successfully integrated technology into patient interactions, with over 300,000 patients registered on the AdaptHealth app, enhancing communication and order management [11][12] - AdaptHealth's operational model is designed to reduce administrative burdens for payers by consolidating DME services under a single provider, improving efficiency and patient satisfaction [73][74]

Group 1 - Approximately 33 million to 34 million Americans suffer from obstructive sleep apnea (OSA), but only 20% are aware and receiving treatment, indicating a significant underdiagnosed population [1] - The rise of wearables, such as oral rings and Apple Watches, is enhancing the detection of potential sleep apnea cases, leading to record wait times for sleep center appointments [2] - The increase in at-home sleep test companies is facilitating the identification of sleep apnea in patients, following referrals from their physicians once diagnosed [2]

AdaptHealth Conference Call Summary Company Overview - **Company**: AdaptHealth (NasdaqCM: AHCO) - **Industry**: Sleep Apnea and Respiratory Equipment Key Points Sleep Apnea Market Insights - Approximately **33-34 million Americans** suffer from obstructive sleep apnea (OSA), with only **20%** diagnosed and treated, indicating a significant underdiagnosed population [2][38] - The market is expected to grow at a rate of **low to mid-single digits** annually [40] - AdaptHealth holds about **25%** of the U.S. CPAP market, significantly larger than any competitor [41] Patient Adherence and Revenue Model - AdaptHealth reports an adherence rate of over **80%**, compared to the industry average of just over **70%** [9][7] - The company receives approximately **$60 per month** from Medicare for CPAP rentals over a **13-month** period, with an average resupply order costing about **$200** [25][11] - Patients are typically resupplied just under **three times a year**, compared to the industry average of **two times** [11] Operational Efficiency - The average setup time for patients has improved from **17 days** to **9 days**, enhancing patient satisfaction and referral rates [35] - AdaptHealth employs **700 sales representatives** to maintain relationships with referring physicians, ensuring a steady flow of patient referrals [33] Growth Strategies - The company is expanding its presence on the **West Coast** with **30 new locations** and an acquisition in Hawaii, aiming to capture more market share in previously underserved areas [42][43] - AdaptHealth is actively pursuing additional capitated contracts, with a dedicated team working on pricing and competitive bids [114] Regulatory Environment - The **CMS** has increased the fee schedule by just over **2%** for 2026, which is beneficial for the industry [105] - The **SOAR Act** is being lobbied to increase reimbursement levels for respiratory services, which is a significant category for AdaptHealth [109] Competitive Landscape - AdaptHealth has not seen any impact from competitors claiming preferred status with payers, maintaining stable referral patterns [95][96] - The company views competitive bidding as an opportunity for consolidation and market share growth, especially in the CGM distribution segment [91][92] Financial Performance - Adjusted EBITDA margins for sleep and respiratory segments run in the **high 20%** range, with gross margins around **60%** for resupply costs [118][119] Challenges and Opportunities - The transition of patients from incumbent providers is complex, but AdaptHealth is leveraging lessons learned from previous contracts to streamline this process [68] - The company is focused on enhancing its core offerings rather than diversifying into new product lines, given the significant growth potential within existing markets [113] Additional Insights - AdaptHealth's proactive approach to patient adherence and operational efficiency positions it well for future growth in the sleep apnea and respiratory equipment markets [6][20] - The company is committed to maintaining high patient satisfaction to ensure continued referrals from healthcare providers [34][122]

Business Operations - AdaptHealth serviced approximately 4.3 million patients annually across all 50 states through a network of about 640 locations as of December 31, 2025[25]. - AdaptHealth completed an average of approximately 38,500 equipment and supply deliveries per day during the year ended December 31, 2025[42]. - As of December 31, 2025, AdaptHealth employed approximately 10,900 individuals[43]. - AdaptHealth's business is dependent on the proper functioning of its information systems, and any significant disruptions could materially affect operations and financial results[87]. - AdaptHealth's operations involve the transport of medical gases, which carries inherent risks and regulatory compliance requirements[111]. - The company has centralized processes in areas like revenue cycle management to enhance productivity, but failure to implement these changes successfully could harm financial results[145]. - AdaptHealth's corporate headquarters spans approximately 22,600 square feet, with all facilities leased to support operational needs[203]. Revenue Sources - For the year ended December 31, 2025, resupply and one-time sale products accounted for approximately 63% of AdaptHealth's net revenue[27]. - Fixed monthly payments for certain home medical equipment products represented approximately 33% of AdaptHealth's net revenue for the year ended December 31, 2025[28]. - At-risk capitation arrangements contributed approximately 4.0% to AdaptHealth's net revenue for the year ended December 31, 2025[31]. - AdaptHealth derived approximately 61% of its net revenue for the years ended December 31, 2025 and 2024, from third-party private payors[95]. - Approximately 42% and 41% of AdaptHealth's net revenue for the years ended December 31, 2025 and 2024, respectively, was generated from the provision of sleep therapy equipment and supplies[100]. - AdaptHealth generated approximately 32% and 30% of its net revenue for the years ended December 31, 2025 and 2024, respectively, through the sale of masks, tubing, and other ancillary products related to patients utilizing PAP devices[98]. - AdaptHealth derived approximately 26% of its net revenue for both the years ended December 31, 2025 and 2024, from Medicare and various state-based Medicaid programs[129]. Regulatory Compliance - AdaptHealth is subject to numerous federal and state laws regarding the collection and handling of protected health information, which may increase compliance costs and potential liabilities[52]. - The California Consumer Privacy Act (CCPA) provides California residents with expanded rights over their personal information, potentially increasing AdaptHealth's compliance costs[52]. - Compliance with healthcare regulations significantly increases the time and costs associated with obtaining and maintaining product approvals, affecting AdaptHealth's operations[57]. - The company faces significant regulatory compliance requirements for its medical gas facilities, which could result in enforcement actions if not maintained[112]. - AdaptHealth is subject to increased scrutiny under federal and state healthcare fraud laws, which could lead to substantial penalties if compliance is not met[135]. - The U.S. Attorney's Office issued civil investigative demands regarding potential false claims related to billing for humidifiers and respiratory devices, with investigations ongoing[139][140]. - Changes in Medicare and Medicaid reimbursement policies could materially affect AdaptHealth's revenue and profitability[130]. - The Patient Protection and Affordable Care Act mandates that overpayments must be reported and returned within 60 days, with a six-year lookback period for reporting[152]. Financial Risks - AdaptHealth has been negatively impacted by inflation, which affects manufacturing and distribution costs, and may not be able to pass these costs onto customers[85]. - Future increases in interest rates could raise interest expenses related to AdaptHealth's variable rate indebtedness, adversely affecting cash flow and financial condition[86]. - AdaptHealth may face challenges in generating sufficient cash flow to cover required payments under long-term debt and operating leases, which could lead to defaults[172]. - The company may require additional capital for growth and may not be able to obtain it on acceptable terms, potentially limiting its expansion plans[174]. - The company has no current plans to pay cash dividends on its Common Stock for the foreseeable future, which may affect returns for investors[187]. - The potential cash payments under the Tax Receivable Agreement (TRA) could be significant and depend on various future events, including the timing of exchanges of AdaptHealth Units and the company's taxable income generation[190]. Market and Competitive Environment - The company is focused on growth through accretive acquisitions and continuously reviews its pipeline of potential acquisition candidates[40]. - The company may face increased competition for acquisition candidates, potentially limiting growth opportunities and increasing acquisition costs[118]. - Consolidation among health insurers may result in increased negotiating leverage against AdaptHealth, affecting its ability to negotiate favorable terms[101]. - The introduction of new drugs for obesity and type 2 diabetes may limit the prospects for AdaptHealth's current equipment or services[109]. - The anticipated use of AI technologies could create operational risks and competitive harm for AdaptHealth[110]. Cybersecurity - The risk of cybersecurity breaches has increased, which could lead to operational disruptions and significant financial penalties[92]. - AdaptHealth's cybersecurity program includes physical, technical, and administrative measures to manage risks, overseen by senior executives with extensive experience in cybersecurity[198][201]. - The company has not identified any significant cybersecurity incidents that materially affect its business or financial condition during the reporting period[200]. Goodwill and Impairment - AdaptHealth recorded $2.5 billion of goodwill on its Consolidated Balance Sheets as of December 31, 2025, which is subject to annual impairment testing[170]. - A non-cash goodwill impairment charge of $128.0 million was recognized for the Diabetes Health reporting unit during the year ended December 31, 2025[171]. - The estimated fair value of the Wellness at Home reporting unit was less than 10% above its carrying value, while the Respiratory Health reporting unit was less than 20% above its carrying value[171]. Operational Challenges - Supply chain disruptions and labor shortages in the U.S. have negatively impacted AdaptHealth's business, leading to increased costs and operational challenges[82]. - AdaptHealth relies on a relatively small number of suppliers for the majority of its patient service equipment, which could adversely affect its operations if there are significant price increases or supply disruptions[81]. - Changes in governmental or private payor supply replenishment schedules could adversely affect AdaptHealth's revenue and operations[98]. - AdaptHealth's revenue may be impacted by the complex reimbursement process, which can involve lengthy delays[99]. - AdaptHealth faces increased risks of audits and payment denials due to inadequate documentation by treating physicians, which could materially impact future revenues and cash flows from government healthcare programs[151].

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - AdaptHealth reported a challenging Q4 2025 with a net revenue of $846.3 million, down 1.2% year over year, attributed mainly to business dispositions in the Wellness at Home segment [5][6] - The company achieved full-year net revenue of $3.245 billion, slightly down 0.5% from the previous year, but with organic growth of 1.7% [6][7] - Management highlighted record patient census in multiple segments, indicating strong operational performance despite revenue declines [5][11] Financial Performance - Q4 net revenue breakdown: - Wellness at Home: $137.3 million, down 16.1% [2] - Diabetes Health: $158.5 million, down 7.4% [3] - Respiratory Health: $178.2 million, up 7.8% [4] - Sleep Health: $372.3 million, up 4.4% [4] - Adjusted EBITDA for 2025 was $616.7 million, with a margin of 19.0%, while Q4 Adjusted EBITDA was $163.1 million, with a margin of 19.3% [8] - Free cash flow for Q4 was $79.3 million, and for the full year, it was $219.4 million, exceeding guidance [9] Operational Developments - The company implemented a new operating model in 2025 to standardize workflows and improve service delivery, resulting in improved setup times for Sleep Health and Respiratory Health [11] - Technology pilots, including AI tools for order intake and patient scheduling, are expected to enhance operational efficiency in the future [12] - A new capitated contract went live in December 2025, covering about 50,000 members, with expectations to serve over 10 million patients nationwide [13] Guidance and Future Outlook - For 2026, AdaptHealth expects revenue growth of 6%-8% over 2025, with organic growth of 7.5%-9.5% [15] - Q1 2026 revenue growth is projected at 2%-3% year over year, with an Adjusted EBITDA margin of approximately 16% [16] - The company anticipates negative free cash flow in Q1 2026, with improvements expected as capitated revenue ramps up [16] Strategic Initiatives - AdaptHealth expanded its footprint with a Hawaii-based HME acquisition, marking its presence in the 48th state [17] - The company received a favorable outcome from CMS regarding competitive bidding, providing long-term stability for its core products [18] - A $14.5 million legal settlement related to a debt collection class action was finalized, with improvements in the company's control environment noted [19][20]

分组1 - AdaptHealth Corp. reported quarterly earnings of $0.27 per share, missing the Zacks Consensus Estimate of $0.34 per share, and down from $0.39 per share a year ago, representing an earnings surprise of -19.81% [1] - The company posted revenues of $846.29 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 1.99%, but down from $856.65 million year-over-year [2] - AdaptHealth has not surpassed consensus EPS estimates over the last four quarters, although it has topped consensus revenue estimates three times during the same period [2] 分组2 - The stock has increased approximately 3.3% since the beginning of the year, while the S&P 500 has declined by 0.1% [3] - The current consensus EPS estimate for the upcoming quarter is $0.02 on revenues of $796.07 million, and for the current fiscal year, it is $0.94 on revenues of $3.45 billion [7] - The Medical - Products industry, to which AdaptHealth belongs, is currently ranked in the bottom 45% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

Financial Data and Key Metrics Changes - Full-year revenue for 2025 was $3.245 billion, a decrease of 0.5% compared to the prior year, while Q4 revenue was $846.3 million, down 1.2% year-over-year but up 1.7% on an organic basis [16][17] - Adjusted EBITDA for the full year was $616.7 million with an Adjusted EBITDA Margin of 19.0%, while Q4 Adjusted EBITDA was $163.1 million with a margin of 19.3% [19][20] - Free Cash Flow for the full year was $219.4 million, exceeding the top end of guidance [21] Business Line Data and Key Metrics Changes - Sleep Health net revenue was $372.3 million, up 4.4% year-over-year, with new starts approximately 130,600, reflecting a 6% increase [17] - Respiratory Health net revenue was $178.2 million, up 7.8% year-over-year, with oxygen and vent new starts increasing by 4% and 5% respectively [18] - Diabetes Health net revenue was $158.5 million, down 7.4% year-over-year, with patient retention at an all-time record but new starts remaining soft [18] - Wellness at Home net revenue declined by 16.1% due to the disposition of non-core assets, although new starts for wheelchairs and beds increased by 6% and 5% respectively [19] Market Data and Key Metrics Changes - Patient census records were set in Sleep Health, Respiratory Health, and Wellness at Home, with significant growth in patient numbers across these segments [4][5] - The company achieved a flat year-over-year patient census in Diabetes Health, with improved retention offsetting slower new starts [6] Company Strategy and Development Direction - The company implemented a new operating model in 2025 aimed at standardization and process maturity, which is expected to drive accelerated growth and improved financial performance in 2026 [3] - The focus remains on debt reduction and strengthening the balance sheet, with $250 million in debt paid down during the year [7][23] - The company is actively pursuing acquisitions to expand its footprint and increase patient access, while also targeting home medical equipment providers [14][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to meet performance requirements under the new capitated contract, which is the largest service transition in the home medical equipment industry [10][11] - The company anticipates revenue growth of 6%-8% for 2026, driven by the new capitated agreement and other business segments [24] - Management highlighted the importance of operational improvements and technology investments in enhancing service delivery and patient engagement [9][10] Other Important Information - The company received favorable outcomes from CMS regarding competitive bidding, providing stability for core products [14] - A legal settlement of $14.5 million was finalized, addressing a civil debt collection class action, which management believes will de-risk the business moving forward [29][30] Q&A Session Summary Question: Clarification on the legal settlement - The settlement is final and covers all claims related to the technicality in debt collection practices, with steps taken to prevent similar issues in the future [29][30] Question: Impact of investment on guidance and margin cadence - The company expects revenue growth to ramp up throughout the year, with Adjusted EBITDA Margin improving as the new capitated arrangement takes effect [36][38] Question: Pipeline of capitated agreements - Management noted ongoing conversations regarding new capitated arrangements, indicating market interest in aligning incentives [44][45] Question: Update on diabetes segment growth - The company is optimistic about improving new starts in the diabetes segment, supported by a growing sales force and operational improvements [48][49] Question: Infrastructure readiness for new healthcare system partnership - The company is on track with initial outlooks, having made key investments to support upcoming start dates for the capitated arrangement [52][53]

Financial Data and Key Metrics Changes - Full-year revenue for 2025 was $3.245 billion, a decrease of 0.5% compared to the prior year, while Q4 revenue was $846.3 million, down 1.2% year-over-year but up 1.7% on an organic basis [16][17] - Adjusted EBITDA for the full year was $616.7 million with an Adjusted EBITDA Margin of 19.0%, while Q4 Adjusted EBITDA was $163.1 million with a margin of 19.3% [19][20] - Free Cash Flow for the full year was $219.4 million, exceeding the top end of guidance [21] Business Line Data and Key Metrics Changes - Sleep Health net revenue was $372.3 million, up 4.4% year-over-year, with new starts approximately 130,600, reflecting a 6% increase [17] - Respiratory Health net revenue was $178.2 million, up 7.8% year-over-year, with oxygen and vent new starts increasing by about 4% and 5% respectively [18] - Diabetes Health net revenue was $158.5 million, down 7.4% year-over-year, with patient retention at an all-time record but new starts remaining soft [18] - Wellness at Home net revenue declined by 16.1% primarily due to the disposition of non-core assets [19] Market Data and Key Metrics Changes - Patient census records were set in Sleep Health, Respiratory Health, and Wellness at Home, with significant growth in patient numbers across these segments [4][5] - The company achieved a flat year-over-year patient census in Diabetes Health, with improved retention offsetting slower new starts [6] Company Strategy and Development Direction - The company implemented a new operating model in 2025 aimed at standardization and process maturity, which is expected to drive accelerated growth and improved financial performance in 2026 [3] - The focus remains on debt reduction and strengthening the balance sheet, with $250 million in debt reduced during the year [7][22] - The company is actively pursuing acquisitions to expand its footprint and increase patient access, while also targeting home medical equipment providers [14][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the operational foundation and strategic focus, stating that the company is in the best condition it has ever been as it enters 2026 [15] - The company anticipates revenue growth of 6%-8% for 2026, driven by new capitated agreements and organic growth [24] - Management highlighted the importance of aligning incentives in the healthcare market and the ongoing interest in capitated arrangements [44] Other Important Information - The company received favorable outcomes from CMS regarding competitive bidding, providing stability for core products [14] - A legal settlement of $14.5 million was finalized, addressing a civil debt collection class action, which management believes will de-risk the business moving forward [29][30] Q&A Session Summary Question: Clarification on the legal settlement - Management confirmed the settlement relates to a civil debt collection class action and is final, addressing all claims in that state [29][30] Question: Impact of investment on guidance and margin cadence - Management provided insights on expected revenue growth and Adjusted EBITDA margin improvements throughout 2026, with specific quarterly expectations [36][38] Question: Pipeline of capitated agreements - Management discussed ongoing conversations and market interest in capitated arrangements, emphasizing the time required to finalize such contracts [44][46] Question: Update on diabetes segment growth - Management noted improvements in retention and plans to grow the diabetes sales force to enhance new starts in 2026 [48][49] Question: Infrastructure readiness for new healthcare partnerships - Management confirmed readiness for upcoming start dates and highlighted investments made to support new capitated arrangements [52][53]